Janus Henderson Global Life Sciences I JFNIX
Set alert
92.86 USD -0.58 -0.62%
At close · Nov 2
Day range unavailable
75.57 52-week range 94.43
- YTD
- +14.42%
- 1 year
- +19.36%
- Open
- —
- Prev close
- 93.44
- Mkt cap
- 5.76B
- Vol
- 0
- Avg vol
- 0
- EPS
- 3.02
- P/E
- 30.73
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 89.47
- 200-d avg
- 84.57
2Y chart
Events in this range
- Dec 6, 2024Dividend: 3.99969
- Dec 5, 2025Dividend: 3.71003
Signals (93)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
Newest 20 of 93.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 30.92
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 89.47
- 200-day average
- 84.57
About Janus Henderson Global Life Sciences I
The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on JFNIX — it syncs with the Stock Master app.